Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.

H Yasui,Y Okita,M Nakamura, T Sagawa,T Watanabe,K Kataoka,D Manaka, K Shiraishi, N Akazawa,T Okuno, T Shimura,M Shiozawa,Y Sunakawa,H Ota, M Kotaka, H Okuyama, M Takeuchi,W Ichikawa,M Fujii,A Tsuji

ESMO open（2023）

引用 0|浏览9

暂无评分

摘要

Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen.

查看译文

关键词

metastatic colorectal cancer,colorectal cancer,antibody,folfiri,second-line,wild-type,anti-egfr

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要